Table 3.
The Impact of Clarithromycin and Metronidazole Resistance on the Evolution of Gastric Lesions
Histologic lesions | Clarithromycin-resistance (%) | Clarithromycin- suceptibility (%) |
Metronidazole-resistance (%) | Metronidazole- suceptibility (%) |
---|---|---|---|---|
Chronic gastritis | 8 (13,3) | 52 (86.7) | 67 (62) | 41 (38) |
Precancerous lesions | 6 (16,7) | 30 (83.3) | 49 (63,6) | 28 (36.4) |
P-value | 0.76 | 0.87 |